8-K: Day One Biopharmaceuticals Announces Preliminary 2024 Revenue and Provides Corporate Update

Day One Biopharmaceuticals reported preliminary unaudited 2024 OJEMDA net product revenue of approximately $57.2 million and ended the year with approximately $531.7 million in cash, cash equivalents, and short-term investments.

Summary

• Day One Biopharmaceuticals announced preliminary unaudited OJEMDA net product revenue of approximately $57.2 million for 2024.
• The company's fourth-quarter OJEMDA net product revenue was approximately $29.0 million.
• Day One ended 2024 with approximately $531.7 million in cash, cash equivalents, and short-term investments, compared to $366.3 million at the end of 2023.
• The company expects to complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial in the first half of 2026.
• The first dose cohort in the Phase 1a portion of the DAY301 Phase 1a/b clinical trial was cleared in January 2025.
• Day One is focused on driving OJEMDA revenue, investing in development programs, and maintaining a strong financial position.
• The company is also pursuing business development opportunities to expand its pipeline.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue figures, a solid cash position, and progress in clinical trials. The company's focus on growth and pipeline expansion is encouraging, although there are inherent risks in the pharmaceutical industry.

Positives

• OJEMDA achieved significant revenue in its first year post-approval, with $57.2 million in net product revenue.
• The company has a strong cash position of approximately $531.7 million, providing financial stability.
• The company is progressing its pipeline with the advancement of the FIREFLY-2 and DAY301 clinical trials.
• Day One has secured an exclusive licensing agreement with Ipsen to commercialize tovorafenib outside of the U.S.
• The reduction in the Medicaid and 340B minimum rebate percentage for OJEMDA will improve profitability.

Negatives

• The financial results are preliminary and unaudited, subject to adjustments.
• The company is still in the early stages of commercializing OJEMDA and faces the challenge of increasing prescriber adoption.
• The FIREFLY-2 trial enrollment is not expected to be completed until the first half of 2026, which is a long time horizon.

Risks

• The preliminary financial results may differ materially from the actual results after the financial close process.
• The company's success depends on the continued growth of OJEMDA revenue and the successful development of its pipeline.
• Clinical trial outcomes are uncertain and may not lead to regulatory approvals.
• The company faces competition from other pharmaceutical companies in the development of cancer therapies.
• Global business and macroeconomic conditions, including inflation and interest rates, could impact the company's operations.

Future Outlook

Day One aims to continue growing OJEMDA revenue, advance its pipeline programs, and maintain a self-sustaining financial position. The company plans to pursue business development opportunities to expand its pipeline and expects to complete enrollment in the FIREFLY-2 trial in the first half of 2026.

Management Comments

• We started 2025 with tremendous momentum based on our 2024 achievements and are well positioned to further our mission, said Jeremy Bender, Ph.D., chief executive officer of Day One.
• Our priorities this year are to drive OJEMDA revenue, to continue investing in programs that leverage our expertise in development and commercialization, and to maintain a strong and durable financial position that allows us to operate independently from capital markets.

Industry Context

This announcement comes as Day One is establishing itself as a player in the pediatric oncology space, particularly in the treatment of low-grade glioma. The company's focus on targeted therapies and its recent commercial success with OJEMDA position it well within the current industry trend of personalized medicine and precision oncology.

Comparison to Industry Standards

• Day One's $57.2 million in first-year revenue for OJEMDA is a strong start for a newly launched oncology drug, but it is difficult to compare directly to other companies without knowing the specific market size and pricing of competing therapies.
• Companies like Novartis with Tafinlar and Mekinist, which target BRAF and MEK mutations, have established a precedent for targeted therapies in oncology, but these are not directly comparable as they are not specifically for pLGG.
• The $531.7 million cash position is robust for a company of Day One's size and stage, providing a solid foundation for future development and commercialization efforts. This is comparable to other biotech companies at a similar stage of development.
• The FIREFLY-2 trial is a key driver for future growth, and its success will be critical for Day One's long-term prospects. The trial is comparable to other Phase 3 trials in oncology, but the specific design and endpoints are unique to the pLGG indication.

Stakeholder Impact

• Shareholders will be encouraged by the strong revenue and cash position, as well as the progress in clinical trials.
• Employees will be motivated by the company's growth and the potential to bring new therapies to patients.
• Patients and their families will benefit from the development of new treatments for pLGG.
• Customers (healthcare providers) will have a new treatment option for pLGG patients.
• Suppliers and creditors will be reassured by the company's financial stability.

Next Steps

• Continue to grow OJEMDA revenue in relapsed or refractory pLGG.
• Advance the existing pipeline, including the FIREFLY-2 Phase 3 clinical trial and DAY301 in the Phase 1a/b trial.
• Pursue business development opportunities to expand the pipeline.
• Maintain a self-sustaining financial position for investing in durable growth.
• Complete enrollment in the FIREFLY-2 Phase 3 clinical trial in the first half of 2026.
• Issue full financial results for the fourth-quarter and full-year 2024 in February 2025.

Key Dates

Keywords

OJEMDA, tovorafenib, DAY301, pLGG, pediatric low-grade glioma, clinical trial, revenue, biopharmaceutical, cancer therapy, BRAF, antibody-drug conjugate, ADC, FIREFLY-2, PTK7